AIMS: To investigate whether cigarette smoking and/or depression contribute to neonatal abstinence syndrome (NAS) severity. DESIGN: Cohort study analyzing data from a randomized, controlled trial of methadone versus buprenorphine. SETTING: Seven study sites that randomized patients to study conditions and provided comprehensive addiction treatment to pregnant patients. PARTICIPANTS: 119 of 131 opioid-dependent pregnant patients who completed the MOTHER study. MEASUREMENTS: Smoking data and depression status were obtained from the Addiction Severity Index and Mini International Neuropsychiatric Interview, respectively. Neonatal outcomes (birth weight, preterm delivery and NAS pharmacologic treatment) were collected from the medical charts. Study site was a fixed-effect factor in all analyses. FINDINGS:Cigarette smoking was reported by 94% of participants and depression identified in 35%. Smoking was associated with low birth weight, preterm delivery, and NAS pharmacologic treatment in both depressed and non-depressed participants. The association between smoking and NAS treatment differed significantly between depressed and non-depressed participants. Among non-depressed participants, adjusting for site and illicit drug use, each additional average cigarette per day (CPD) increased the odds of NAS treatment by 12% [95%CI: (1.02-1.23), p=0.02]. Among depressed participants, each additional average CPD did not statistically increase the odds of NAS treatment [OR: 0.94, 95% CI: (0.84-1.04), p=0.23]. CONCLUSIONS: These results are consistent with the hypothesis that NAS expression is influenced by many factors. The relationship between CPD and NAS pharmacologic treatment is attenuated among depressed women in this study for reasons currently unknown. Further investigations are needed to clarify the complex relationships among maternal smoking, depression, and NAS.
RCT Entities:
AIMS: To investigate whether cigarette smoking and/or depression contribute to neonatal abstinence syndrome (NAS) severity. DESIGN: Cohort study analyzing data from a randomized, controlled trial of methadone versus buprenorphine. SETTING: Seven study sites that randomized patients to study conditions and provided comprehensive addiction treatment to pregnant patients. PARTICIPANTS: 119 of 131 opioid-dependent pregnant patients who completed the MOTHER study. MEASUREMENTS: Smoking data and depression status were obtained from the Addiction Severity Index and Mini International Neuropsychiatric Interview, respectively. Neonatal outcomes (birth weight, preterm delivery and NAS pharmacologic treatment) were collected from the medical charts. Study site was a fixed-effect factor in all analyses. FINDINGS: Cigarette smoking was reported by 94% of participants and depression identified in 35%. Smoking was associated with low birth weight, preterm delivery, and NAS pharmacologic treatment in both depressed and non-depressedparticipants. The association between smoking and NAS treatment differed significantly between depressed and non-depressedparticipants. Among non-depressedparticipants, adjusting for site and illicit drug use, each additional average cigarette per day (CPD) increased the odds of NAS treatment by 12% [95%CI: (1.02-1.23), p=0.02]. Among depressed participants, each additional average CPD did not statistically increase the odds of NAS treatment [OR: 0.94, 95% CI: (0.84-1.04), p=0.23]. CONCLUSIONS: These results are consistent with the hypothesis that NAS expression is influenced by many factors. The relationship between CPD and NAS pharmacologic treatment is attenuated among depressed women in this study for reasons currently unknown. Further investigations are needed to clarify the complex relationships among maternal smoking, depression, and NAS.
Authors: Kaviraja Udupa; T N Sathyaprabha; Jagadisha Thirthalli; K R Kishore; G S Lavekar; T R Raju; B N Gangadhar Journal: J Affect Disord Date: 2006-11-20 Impact factor: 4.839
Authors: Neil S Seligman; Nicole Salva; Edward J Hayes; Kevin C Dysart; Edward C Pequignot; Jason K Baxter Journal: Am J Obstet Gynecol Date: 2008-10 Impact factor: 8.661
Authors: H E Jones; S H Heil; K E O'Grady; P R Martin; K Kaltenbach; M G Coyle; S M Stine; P Selby; A M Arria; G Fischer Journal: Am J Drug Alcohol Abuse Date: 2009 Impact factor: 3.829
Authors: Hendree E Jones; Rolley E Johnson; Donald R Jasinski; Kevin E O'Grady; Christian A Chisholm; Robin E Choo; Michael Crocetti; Robert Dudas; Cheryl Harrow; Marilyn A Huestis; Lauren M Jansson; Michael Lantz; Barry M Lester; Lorraine Milio Journal: Drug Alcohol Depend Date: 2005-07 Impact factor: 4.492
Authors: Sarah J Hemauer; Svetlana L Patrikeeva; Tatiana N Nanovskaya; Gary D V Hankins; Mahmoud S Ahmed Journal: Biochem Pharmacol Date: 2009-07-08 Impact factor: 5.858
Authors: Hendree E Jones; Peter R Martin; Sarah H Heil; Karol Kaltenbach; Peter Selby; Mara G Coyle; Susan M Stine; Kevin E O'Grady; Amelia M Arria; Gabriele Fischer Journal: J Subst Abuse Treat Date: 2008-01-14
Authors: Gerald T Cochran; Valerie Hruschak; Walitta Abdullah; Elizabeth Krans; Antoine B Douaihy; Stephanie Bobby; Rachel Fusco; Ralph Tarter Journal: J Addict Med Date: 2018 Jan/Feb Impact factor: 3.702